Talus Announces Close of Seed Funding Round and Hires New COO
Talus Bioscience is a Seattle-based biotech startup that has developed a platform called MARMOT to discover drugs that target transcription factors, which are proteins that interact with DNA and turn genes on and off. Transcription factors are involved in many diseases, especially cancer, but most of them are hard to drug because they have no clear binding sites for small molecules. Talus Bioscience can measure the amount of transcription factors that are stuck to the DNA inside the cell, and use this information to identify and test potential drugs that can knock them off the DNA, effectively switching off disease-causing genes.
Talus Bio lands $9.75M in new funding to advance its drug discovery platform
The company was founded in 2020 by Alex Federation and Lindsay Pino, who developed the technology as trainees at the University of Washington and the Altius Institute for Biomedical Sciences. The company has raised $9.75 million in seed funding from various investors, including NFX and Y Combinator. The company has also hired a new COO, Michelle Briscoe, who previously served as president and CEO of Brooks Applied Labs.